期刊文献+

病毒与特发性肺纤维化

Virus and idiopathic pulmonary fibrosis
原文传递
导出
摘要 特发性肺纤维化是一种病因不明的、进展性的疾病,有较高的病死率,中位生存期仅3年,缺少有效治疗手段。研究表明病毒感染可导致特发性肺纤维化的发生、发展及急性加重,抗病毒治疗有可能缓解症状,延缓病情进展。本文主要阐述病毒感染作为特发性肺纤维化发病原因的依据,并通过肺纤维化动物模型来探讨其可能机制。 Idiopathic pulmonary fibrosis (IPF) is a disease of unknown origin and progression. The mortality of IPF is higher,median survival time is three years. This is due to lack of effective therapies to halt disease progression. Accumulating evidences suggest that viral infection may play a key role in the initiation,progression and acute exacerbation of IPF. It is possible that therapeutic strategies, utilising available antiviral, may be effective in halting the progression of IPF. This article summarizes the evidences for the notion that virus may contribute to IPF. In addition, we review mechanistic studies in animal models that highlight the fibrotic potential of viral infection, and explore the different mechanisms.
作者 张劼 李秀娟
出处 《国际呼吸杂志》 2015年第16期1255-1258,共4页 International Journal of Respiration
基金 重庆市渝中区科技计划项目(20130149) 重庆市卫计委医学科研项目(20142012)
关键词 病毒 纤维化 机制 Virus, Pulmonary Fibrosis Mechanism
  • 相关文献

参考文献1

二级参考文献29

  • 1[1]Kobayashi T,Kawa S,Tokoo M,Oguchi H,Kiyosawa K,Furuta S,Kanai M,Homma T.Comparative study of CA-50 (time-resolved fluoroimmunoassay),Span-1,and CA19-9 in the diagnosis of pancreatic cancer.Scand J Gastroenterol 1991; 26:787-797
  • 2[2]Alter MJ,Margolis HS,Krawczynski K,Judson FIN,Mares A,Alexander WJ,Hu PY,Miller JK,Gerber MA,Sampliner RE.The natural history of community-acquired hepatitis C in the United States.The Sentinel Counties Chronic non-A,non-B Hepatitis Study Team.N Engl J Ivied 1992; 327:1899-1905
  • 3[3]van Rossum TG,Vulto AG,de Man RA,Brouwer JT,Schalm SW.Review article:glycyrrhizin as a potential treatment for chronic hepatitis C.Aliment Pharmacol Ther 1998; 12:199-205
  • 4[4]Colombo M,Kuo G,Choo QL,Donato MF,Del Ninno E,Tommasini MA,Dioguardi N,Houghton M.Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma.Lancet 1989; 2:1006-1008
  • 5[5]Hasan F,Jeffers LJ,De Medina M,Reddy KR,Parker T,Schiff ER,Houghton M,Choo QL,Kuo G.Hepatitis C-associated hepatocellular carcinoma.Hepatology 1990; 12:589-591
  • 6[6]Kew MC,Houghton M,Choo QL,Kuo G.Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma.Lancet 1990; 335:873-874
  • 7[7]Tsukuma H,Hiyama T,Tanaka S,Nakao M,Yabuuchi T,Kitamura T,Nakanishi K,Fujimoto I,Inoue A,Yamazaki H.Risk factors for hepatocellular carcinoma among patients with chronic liver disease.N Engl J Med 1993; 328:1797-1801
  • 8[8]Ikeda K,Saitoh S,Koida I,Arase Y,Tsubota A,Chayama K,Kumada H,Kawanishi M.A multivariate analysis of risk factors for hepatoceUular carcinogenesis:a prospective observation of 795 patients with viral and alcoholic cirrhosis.Hepatology 1993; 18:47-53
  • 9[9]Gumber SC,Chopra S.Hepatitis C:a multifaceted disease.Review of extrahepatic manifestations.Ann Intern ivied 1995; 123:615-620
  • 10[10]Zignego AL,Ferri C,Giannini C,Monti M,La Civita L,Careccia G,Longombardo G,Lombardini F,Bombardieri S,Gentilini P.Hepatitis C virus genotype analysis in patients with type Ⅱ mixed cryoglobulinemia.Ann Intern Med 1996; 124:31-34

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部